QSAR analysis of nicotinamidic compounds and design of potential Bruton’s tyrosine kinase (Btk) inhibitors

References

• Akinleye, A., Chen, Y. M., Mukhi, N., Song, Y. P., & Liu, D. L. (2013). Ibrutinib and novel BTK inhibitors in clinical development. Journal of Hematology & Oncology, 6, 1756–8722.
   Google Scholar
• Allinger, N. L. (1977). Conformational analysis. 130. MM2. A hydrocarbon force field utilizing V1 and V2 torsional terms. Journal of the American Chemical Society, 99, 8127–8134.10.1021/ja00467a001
   Web of Science ®Google Scholar
• Berman, H. M., Battistuz, T., Bhat, T. N., Bluhm, W. F., Bourne, P. E., Burkhardt, K., … Zardecki, C. (2002). The Protein Data Bank. Acta Crystallographica Section D-Biological Crystallography, 58, 899–907.10.1107/S0907444902003451
   PubMed Web of Science ®Google Scholar
• Bolen, J. B. (1995). Protein-tyrosine kinases in the initiation of antigen receptor signaling. Current Opinion in Immunology, 7, 306–311.10.1016/0952-7915(95)80103-0
   PubMed Web of Science ®Google Scholar
• Brown, J. R. (2013). Ibrutinib (PCI-32765), the first BTK (Bruton’s tyrosine kinase) inhibitor in clinical trials. Current Hematologic Malignancy Reports, 8, 1–6.10.1007/s11899-012-0147-9
   PubMed Web of Science ®Google Scholar
• da Cunha, E. F. F., Albuquerque, M. G., Antunes, O. A. C., & de Alencastro, R. B. (2005). 4D-QSAR models of HOE/BAY-793 analogues as HIV-1 protease inhihitors. QSAR & Combinatorial Science, 24, 240–253.
   Google Scholar
• da Cunha, E. F. F., Mancini, D. T., & Ramalho, T. C. (2012). Molecular modeling of the Toxoplasma gondii adenosine kinase inhibitors. Medicinal Chemistry Research, 21, 590–600.10.1007/s00044-011-9554-z
   Web of Science ®Google Scholar
• da Cunha, E. F. F., Martins, R. C. A., Albuquerque, M. G., & Alencastro, R. B. (2004). LIV-3D-QSAR model for estrogen receptor ligands. Journal of Molecular Modeling, 10, 297–304.
   Web of Science ®Google Scholar
• da Cunha, E. F. F., Resende, J. E., Franca, T. C. C., Gonçalves, M. A., de Souza, F. R., Santos-Garcia, L., & Ramalho, T. C. (2013). Molecular modeling studies of piperidine derivatives as new acetylcholinesterase inhibitors against neurodegenerative diseases. Journal of Chemistry, 2013, 1–7.10.1155/2013/278742
   Web of Science ®Google Scholar
• Delucca, G. V., Shi, Q., Liu, C., Duan, J., & Tebben, A. J. (2010). New substituted nicotinamide compounds are Bruton’s tyrosine kinase inhibitors, useful for the treatment or prophylaxis of e.g. ulcerative colitis, asthma, Graves’ disease, rheumatoid arthritis, psoriasis, osteoarthritis and osteoporosis. U.S. Patent No. S2012082702. Washington, DC: U.S. Patent and Trademark Office.
   Google Scholar
• Di Paolo, J. A., Huang, T., Balazs, M., Barbosa, J., Barck, K. H., Bravo, B. J., … Currie, K. S. (2011). Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nature Chemical Biology, 7, 41–50.10.1038/nchembio.481
   PubMed Web of Science ®Google Scholar
• Emelie, K., Blomberg, M., Smith, C. I. E., & Lindvall, J. M. (2007). Gene expression signatures in primary immunodeficiencies: The experience from human disease and mouse models. Current Molecular Medicine, 7, 555–566.
   PubMed Web of Science ®Google Scholar
• Hantschel, O., Rix, U., Schmidt, U., Burckstummer, T., Kneidinger, M., Schutze, G., …Superti-Furga, G. (2007). The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proceedings of the National Academy of Sciences of the United States of America, 104, 13283–13288.10.1073/pnas.0702654104
   PubMed Web of Science ®Google Scholar
• Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., …Buggy, J. J. (2010). The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proceedings of the National Academy of Sciences of the United States of America, 107, 13075–13080.10.1073/pnas.1004594107
   PubMed Web of Science ®Google Scholar
• Hopfinger, A. J., Wang, S., Tokarski, J. S., Jin, B. Q., Albuquerque, M., Madhav, P. J., & Duraiswami, C. (1997). Construction of 3D-QSAR models using the 4D-QSAR analysis formalism. Journal of the American Chemical Society, 119, 10509–10524.10.1021/ja9718937
   Web of Science ®Google Scholar
• Hyvonen, M., & Saraste, M. (1997). Structure of the PH domain and Btk motif from Bruton’s tyrosine kinase: Molecular explanations for X-linked agammaglobulinaemia. The EMBO Journal, 16, 3396–3404.10.1093/emboj/16.12.3396
   PubMed Web of Science ®Google Scholar
• Janda, E., Palmieri, C., Pisano, A., Pontoriero, M., Iaccino, E., Falcone, C., … Scala, G. (2011). Btk regulation in human and mouse B cells via protein kinase C phosphorylation of IBtkγ. Blood, 117, 6520–6531.10.1182/blood-2010-09-308080
   PubMed Web of Science ®Google Scholar
• Kiralj, R., & Ferreira, M. M. C. (2009). Basic validation procedures for regression models in QSAR and QSPR studies: Theory and application. Journal of the Brazilian Chemical Society, 20, 770–787.10.1590/S0103-50532009000400021
   Web of Science ®Google Scholar
• Kurosaki, T. (1997). Molecular mechanisms in B cell antigen receptor signaling. Current Opinion in Immunology, 9, 309–318.10.1016/S0952-7915(97)80075-1
   PubMed Web of Science ®Google Scholar
• Lou, Y., Owens, T. D., Kuglstatter, A., Kondru, R. K., & Goldstein, D. M. (2012). Bruton’s tyrosine kinase inhibitors: Approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies. Journal of Medicinal Chemistry, 55, 4539–4550.10.1021/jm300035p
   PubMed Web of Science ®Google Scholar
• Marcotte, D. J., Liu, Y. T., Arduini, R. M., Hession, C. A., Miatkowski, K., Wildes, C. P., … Silvian, L. F. (2010). Structures of human Bruton’s tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases. Protein Science, 19, 429–439.
   PubMed Web of Science ®Google Scholar
• Mohamed, A. J., Yu, L., Bäckesjö, C. M., Vargas, L., Faryal, R., Aints, A., … Edvard Smith, C. I. (2009). Bruton’s tyrosine kinase (Btk): Function, regulation, and transformation with special emphasis on the PH domain. Immunological Reviews, 228, 58–73.10.1111/imr.2009.228.issue-1
   PubMed Web of Science ®Google Scholar
• Muri, E. M. F., Gomes, M., Costa, J. S., Alencar, F. L., Sales, A., Bastos, M. L., … Antunes, O. A. C. (2004). N-t-Boc-amino acid esters of isomannide – Potential inhibitors of serine proteases. Amino Acids, 27, 153–159.10.1007/s00726-004-0121-5
   PubMed Web of Science ®Google Scholar
• Oliveira, A. A., Ramalho, T. C., & da Cunha, E. F. F. (2009). QSAR study of androstenedione analogs as aromatase inhibitors. Letters in Drug Design & Discovery, 6, 554–562.
   Web of Science ®Google Scholar
• Pan, Z., Scheerens, H., Li, S.-J., Schultz, B. E., Sprengeler, P. A., Burrill, L. C., … Palmer, J. T. (2007). Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase. ChemMedChem, 2, 58–61.10.1002/(ISSN)1860-7187
   PubMed Web of Science ®Google Scholar
• Pan, D. H., Tseng, Y. F., & Hopfinger, A. J. (2003). Quantitative structure-based design: Formalism and application of receptor-dependent RD-4D-QSAR analysis to a set of glucose analogue inhibitors of glycogen phosphorylase. Journal of Chemical Information and Modeling, 43, 1591–1607.10.1021/ci0340714
   Web of Science ®Google Scholar
• Ponader, S., Chen, S. S., Buggy, J. J., Balakrishnan, K., Gandhi, V., Wierda, W. G., … Burger, J. A. (2012). The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood, 119, 1182–1189.10.1182/blood-2011-10-386417
   PubMed Web of Science ®Google Scholar
• Scharenberg, A. M., & Kinet, J. P. (1998). Ptdlns-3,4,5-P3: A regulatory nexus between tyrosine kinases and sustained calcium signals. Cell, 94, 5–8.10.1016/S0092-8674(00)81214-3
   PubMed Web of Science ®Google Scholar
• Silva, D. G., Freitas, M. P., da Cunha, E. F. F., Ramalho, T. C., & Nunes, C. A. (2012). Rational design of small modified peptides as ACE inhibitors. MedChemComm, 3, 1290–1293.10.1039/c2md20214j
   Web of Science ®Google Scholar
• Thangapandian, S., John, S., Sakkiah, S., & Lee, K. W. (2010). Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design. European Journal of Medicinal Chemistry, 45, 4409–4417.10.1016/j.ejmech.2010.06.024
   PubMed Web of Science ®Google Scholar
• Thomas, J. D., Sideras, P., Smith, C. I. E., Vorechovsky, I., Chapman, V., & Paul, W. E. (1993). Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. Science, 261, 355–358.10.1126/science.8332900
   PubMed Web of Science ®Google Scholar
• Tsukada, S., Rawlings, D. J., & Witte, O. N. (1994). Role of Bruton’s tyrosine kinase in immunodeficiency. Current Opinion in Immunology, 6, 623–630.10.1016/0952-7915(94)90151-1
   PubMed Web of Science ®Google Scholar
• Tsukada, S., Saffran, D. C., Rawlings, D. J., Parolini, O., Allen, R. C., Klisak, I., … Witte, O. N. (1993). Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell, 72, 279–290.10.1016/0092-8674(93)90667-F
   PubMed Web of Science ®Google Scholar
• Vargas, L., Hamasy, A., Nore, B. F., & Smith, C. I. E. (2013). Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases. Scandinavian Journal of Immunology, 78, 130–139.10.1111/sji.2013.78.issue-2
   PubMed Web of Science ®Google Scholar
• Vetrie, D., Vořechovský, I., Sideras, P., Holland, J., Davies, A., Flinter, F., … Bentley, D. R. (1993). The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature, 361, 226–233.10.1038/361226a0
   PubMed Web of Science ®Google Scholar
• Vihinen, M., Nilsson, L., & Smith, C. I. E. (1994). Tec homology (TH) adjacent to the PH domain. FEBS Letters, 350, 263–265.10.1016/0014-5793(94)00783-7
   PubMed Web of Science ®Google Scholar